Bio News
Rare disease drug developer Oak Hill Bio will list on the Nasdaq through a SPAC merger, securing a total of $175 million (approximately 262.5 billion won). The funds will be used for a phase 3 clinical trial of lugonersen, a treatment candidate for Angelman syndrome, and to submit a new drug application (NDA) in 2029. Lugonersen is an antisense oligonucleotide (ASO) drug licensed from Roche that works by regulating expression of the UBE3A gene to improve neurological function.
BIOBOOK TEAM
biobookmedia@biobook.co.krRural Development Administration Develops Two Molecular Markers to Identify Leaf Splitting in Squash
MFDS Begins Distribution of Internationally Certified Reference Materials, Including 24 New Items, for a Total of 882
Ministry of Trade, Industry and Energy signs agreement to promote biotech and medical devices in Gangwon; site visit set for the 14th
RDA develops technology to produce anti-inflammatory exosomes for pets and files patent application
HLB Submits FDA Resubmission for First-Line Liver Cancer Treatment
Celltrion Reports Third-Quarter Revenue of 1.5 Trillion Won and Operating Profit of 510 Billion Won, Up 69% Year Over Year
Rural Development Administration Develops Two Molecular Markers to Identify Leaf Splitting in Squash
MFDS Begins Distribution of Internationally Certified Reference Materials, Including 24 New Items, for a Total of 882
Ministry of Trade, Industry and Energy signs agreement to promote biotech and medical devices in Gangwon; site visit set for the 14th
